Our latest articles

Vantage logo

Blueprint for disappointment

Ayvakit hits in its pivotal indolent systemic mastocytosis trial, but a dwindling effect size reignites commercial concerns.

Vantage logo

Viridian takes on Horizon

Early data in thyroid eye disease impress, but unanswered questions include the size of the market.

Vantage logo

Zantac burns big pharma

As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.